These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 23812422)

  • 1. A novel bispecific EGFR/Met antibody blocks tumor-promoting phenotypic effects induced by resistance to EGFR inhibition and has potent antitumor activity.
    Castoldi R; Ecker V; Wiehle L; Majety M; Busl-Schuller R; Asmussen M; Nopora A; Jucknischke U; Osl F; Kobold S; Scheuer W; Venturi M; Klein C; Niederfellner G; Sustmann C
    Oncogene; 2013 Dec; 32(50):5593-601. PubMed ID: 23812422
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual blockade of EGFR and c-Met abrogates redundant signaling and proliferation in head and neck carcinoma cells.
    Xu H; Stabile LP; Gubish CT; Gooding WE; Grandis JR; Siegfried JM
    Clin Cancer Res; 2011 Jul; 17(13):4425-38. PubMed ID: 21622718
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MM-131, a bispecific anti-Met/EpCAM mAb, inhibits HGF-dependent and HGF-independent Met signaling through concurrent binding to EpCAM.
    Casaletto JB; Geddie ML; Abu-Yousif AO; Masson K; Fulgham A; Boudot A; Maiwald T; Kearns JD; Kohli N; Su S; Razlog M; Raue A; Kalra A; Håkansson M; Logan DT; Welin M; Chattopadhyay S; Harms BD; Nielsen UB; Schoeberl B; Lugovskoy AA; MacBeath G
    Proc Natl Acad Sci U S A; 2019 Apr; 116(15):7533-7542. PubMed ID: 30898885
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fc-mediated activity of EGFR x c-Met bispecific antibody JNJ-61186372 enhanced killing of lung cancer cells.
    Grugan KD; Dorn K; Jarantow SW; Bushey BS; Pardinas JR; Laquerre S; Moores SL; Chiu ML
    MAbs; 2017 Jan; 9(1):114-126. PubMed ID: 27786612
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HGF rescues colorectal cancer cells from EGFR inhibition via MET activation.
    Liska D; Chen CT; Bachleitner-Hofmann T; Christensen JG; Weiser MR
    Clin Cancer Res; 2011 Feb; 17(3):472-82. PubMed ID: 21098338
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer.
    Nakagawa T; Takeuchi S; Yamada T; Nanjo S; Ishikawa D; Sano T; Kita K; Nakamura T; Matsumoto K; Suda K; Mitsudomi T; Sekido Y; Uenaka T; Yano S
    Mol Cancer Ther; 2012 Oct; 11(10):2149-57. PubMed ID: 22844075
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of amivantamab (JNJ-61186372), a bispecific antibody targeting EGFR and MET.
    Neijssen J; Cardoso RMF; Chevalier KM; Wiegman L; Valerius T; Anderson GM; Moores SL; Schuurman J; Parren PWHI; Strohl WR; Chiu ML
    J Biol Chem; 2021; 296():100641. PubMed ID: 33839159
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combining onartuzumab with erlotinib inhibits growth of non-small cell lung cancer with activating EGFR mutations and HGF overexpression.
    Sano Y; Hashimoto E; Nakatani N; Abe M; Satoh Y; Sakata K; Fujii T; Fujimoto-Ouchi K; Sugimoto M; Nagahashi S; Aoki M; Motegi H; Sasaki E; Yatabe Y
    Mol Cancer Ther; 2015 Feb; 14(2):533-41. PubMed ID: 25522765
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EGFRvIII and c-Met pathway inhibitors synergize against PTEN-null/EGFRvIII+ glioblastoma xenografts.
    Lal B; Goodwin CR; Sang Y; Foss CA; Cornet K; Muzamil S; Pomper MG; Kim J; Laterra J
    Mol Cancer Ther; 2009 Jul; 8(7):1751-60. PubMed ID: 19584231
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Novel Bispecific Antibody Targeting EGFR and cMet Is Effective against EGFR Inhibitor-Resistant Lung Tumors.
    Moores SL; Chiu ML; Bushey BS; Chevalier K; Luistro L; Dorn K; Brezski RJ; Haytko P; Kelly T; Wu SJ; Martin PL; Neijssen J; Parren PW; Schuurman J; Attar RM; Laquerre S; Lorenzi MV; Anderson GM
    Cancer Res; 2016 Jul; 76(13):3942-53. PubMed ID: 27216193
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fibroblast-secreted hepatocyte growth factor mediates epidermal growth factor receptor tyrosine kinase inhibitor resistance in triple-negative breast cancers through paracrine activation of Met.
    Mueller KL; Madden JM; Zoratti GL; Kuperwasser C; List K; Boerner JL
    Breast Cancer Res; 2012 Jul; 14(4):R104. PubMed ID: 22788954
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel bispecific c-MET/PD-1 antibody with therapeutic potential in solid cancer.
    Sun ZJ; Wu Y; Hou WH; Wang YX; Yuan QY; Wang HJ; Yu M
    Oncotarget; 2017 Apr; 8(17):29067-29079. PubMed ID: 28404966
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dual-targeting of EGFR and Neuropilin-1 attenuates resistance to EGFR-targeted antibody therapy in KRAS-mutant non-small cell lung cancer.
    Kim YJ; Baek DS; Lee S; Park D; Kang HN; Cho BC; Kim YS
    Cancer Lett; 2019 Dec; 466():23-34. PubMed ID: 31521695
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual inhibition of Met kinase and angiogenesis to overcome HGF-induced EGFR-TKI resistance in EGFR mutant lung cancer.
    Takeuchi S; Wang W; Li Q; Yamada T; Kita K; Donev IS; Nakamura T; Matsumoto K; Shimizu E; Nishioka Y; Sone S; Nakagawa T; Uenaka T; Yano S
    Am J Pathol; 2012 Sep; 181(3):1034-43. PubMed ID: 22789825
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of
    Emdal KB; Dittmann A; Reddy RJ; Lescarbeau RS; Moores SL; Laquerre S; White FM
    Mol Cancer Ther; 2017 Nov; 16(11):2572-2585. PubMed ID: 28830985
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel glycoengineered bispecific antibody format for targeted inhibition of epidermal growth factor receptor (EGFR) and insulin-like growth factor receptor type I (IGF-1R) demonstrating unique molecular properties.
    Schanzer JM; Wartha K; Croasdale R; Moser S; Künkele KP; Ries C; Scheuer W; Duerr H; Pompiati S; Pollman J; Stracke J; Lau W; Ries S; Brinkmann U; Klein C; Umana P
    J Biol Chem; 2014 Jul; 289(27):18693-706. PubMed ID: 24841203
    [TBL] [Abstract][Full Text] [Related]  

  • 17. XGFR*, a novel affinity-matured bispecific antibody targeting IGF-1R and EGFR with combined signaling inhibition and enhanced immune activation for the treatment of pancreatic cancer.
    Schanzer JM; Wartha K; Moessner E; Hosse RJ; Moser S; Croasdale R; Trochanowska H; Shao C; Wang P; Shi L; Weinzierl T; Rieder N; Bacac M; Ries CH; Kettenberger H; Schlothauer T; Friess T; Umana P; Klein C
    MAbs; 2016; 8(4):811-27. PubMed ID: 26984378
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Norcantharidin combined with EGFR-TKIs overcomes HGF-induced resistance to EGFR-TKIs in EGFR mutant lung cancer cells via inhibition of Met/PI3k/Akt pathway.
    Wu H; Fan F; Liu Z; Shen C; Wang A; Lu Y
    Cancer Chemother Pharmacol; 2015 Aug; 76(2):307-15. PubMed ID: 26063323
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatocyte growth factor induces resistance to anti-epidermal growth factor receptor antibody in lung cancer.
    Yamada T; Takeuchi S; Kita K; Bando H; Nakamura T; Matsumoto K; Yano S
    J Thorac Oncol; 2012 Feb; 7(2):272-80. PubMed ID: 22089117
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Suppression of c-Met-Overexpressing Tumors by a Novel c-Met/CD3 Bispecific Antibody.
    Huang L; Xie K; Li H; Wang R; Xu X; Chen K; Gu H; Fang J
    Drug Des Devel Ther; 2020; 14():3201-3214. PubMed ID: 32982167
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.